Janus Henderson Group
URGN icon

Janus Henderson Group’s UroGen Pharma URGN Stock Holding History

Janus Henderson Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$343K Buy
+19,100
New +$383K ﹤0.01% 2161
2025
Q1 		– Sell
-14,000
Closed -$149K – 2553
2024
Q4 		$149K Buy
+14,000
New +$168K ﹤0.01% 2481

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Janus Henderson Group's URGN Position: Q1 2026 in Review

Janus Henderson Group opened a new position in UroGen Pharma (URGN) in Q1 2026: 19,100 shares worth $343K. The stake represents ﹤0.01% of the portfolio and ranks #2161 among its holdings. This is a return to the name: Janus Henderson Group previously reported a position in URGN as recently as Q4 2024.

Janus Henderson Group first reported a position in URGN in Q4 2024 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Janus Henderson Group held 19,100 shares of UroGen Pharma worth $343K as of Q1 2026.
  • UroGen Pharma was a new Janus Henderson Group position in Q1 2026.
  • UroGen Pharma made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2161 holding.
  • Janus Henderson Group first reported a position in UroGen Pharma in Q4 2024 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.